Locations:
Search IconSearch
June 12, 2018/Cancer

Robotic Partial Nephrectomy for Tumors that Invade Sinus Fat (Video)

Achieving local cancer control without radical nephrectomy

By Jihad Kaouk, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In this era of robotic surgery, indications for partial nephrectomy (PN) are being widened to more complex renal masses.

In this video, we provide technical hints for achieving local cancer control during transperitoneal robotic PN (RPN) for T3 tumors that invade the sinus fat.

Technique

Our refined robotic technique entails a thorough examination of preoperative imaging and intraoperative renal ultrasound. Excision of the tumor is planned in such a way to shift retraction to the sinus fat. Such retraction allows for delineation of the fat involved with the tumor versus normal sinus fat away from the tumor.

We base our enthusiasm for this technique on a study of masses that underwent RPN at our institution. Of the 1,497 renal masses, 512 were suspected to have sinus fat invasion (RENAL score 3 for nearness to the sinus). Of these, 69 (13.5 percent) had pT3a tumor involving sinus fat at final pathology, representing the analyzed cohort. Twenty-four robotic transperitoneal PN were performed by our refined technique described in this video and 45 PNs were performed by our standard institutional technique.

Overall positive surgical margin (PSM) rate for the analyzed cohort (69 patients) was 11.6 percent. In patients operated on by our standard technique, the PSM rate was higher (0 percent versus 17.8 percent, P = 0.031). We were able to practically eliminate positive margins by refining our technique (P = 0.031). In patients operated on with the revised robotic technique presented on this video, trifecta achievement (no positive margins, no complications and excellent kidney function) was even higher compared to the standard technique (54.2 percent versus 20 percent, P = 0.005).

Advertisement

Differences in PSMs were not reflected in early oncological outcomes. Retrospective analysis and limited follow-up represent study limitations.

Conclusion

With consistent experience in robotic surgery, optimal cancer control can be achieved with this customized robotic approach, especially in cases when tumors involve the renal sinus, which would otherwise require a radical nephrectomy.

Clinical fellow Juan Garisto, MD, and research fellow Riccardo Bertolo, MD, assisted in the production of this video.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad